Summary Human neuroblastoma cells grown as tumour spheroids were briefly incubated with a conjugate of 1311 and an anti-human neuroectodermal monoclonal antibody UJ 1 3A. Unbound 1311 was removed by washing and the spheroids observed in culture conditions for up to 4 weeks. Spheroid response to irradiation was evaluated as time to reach 10x treatment volume and proportion of spheroids sterilised. Spheroid growth was found to be affected by both the activity of 131I-UJ13A and the duration of the incubation. Na[131I], 1311-HSA, 1311 labelled non-specific antibody and unlabelled antibody were found to be relatively ineffective compared to 1311-UJ 1 3A. The tumour spheroid model has applications in the evaluation of antibodies or antibody fragments and different radionuclides which may be considered for radioimmunotherapy of micrometastases.
The use of monoclonal antibodies conjugated to cytotoxic agents as cancer therapy is most promising for the treatment of small numbers of tumour cells, such as sub-clinical metastases (Kemshead, 1985; Wheldon et al., 1988) . Radioimmunotherapy using 1311 conjugated to antibodies is under clinical investigation in several centres (Carrasquillo et al., 1984; Kemshead et al., 1984; Order et al., 1980) . Most experimental work is presently being performed using xenografts of human tumour in nude mice (Hagan et al., 1986; Pimm & Baldwin, 1985) .
Here we describe the use of an in vitro experimental model which is suitable for laboratory assessment of antibodytargeted radiotherapy of microscopic tumours.
Human tumour cell lines may often be grown in the form of tumour spheroids which are cellular aggregates which grow by division in the periphery (Sutherland et al., 1971; Yuhas et al., 1977) . Tumour spheroids in vitro resemble micrometastases during the avascular phase of their development (West et al., 1980) . In these experiments we have grown a human neuroblastoma cell line (NB l-G) in the form of tumour spheroids. The cell line NBI-G is a recently established derivative of a neuroblastoma tumour whose origin, genetics, cytogenetics, antigenicity and radiobiology have been characterised (Wheldon et al., 1985; Carachi et al., 1987) . We have used this spheroid line to evaluate the effectiveness of antibody targeted irradiation of neuroblastoma spheroids with 131I conjugated to the mouse-antihuman neuroectodermal monoclonal antibody UJ13A which has been shown to bind to human neuroblastoma cells (Allan et al., 1983) .
Materials and methods
Monoclonal antibodies UJ 1 3A, a neuroectodermal specific monoclonal antibody (Allan et al., 1983; Kemshead, 1985) was kindly provided by Dr J.T. Kemshead (Imperial Cancer Research Fund) . This antibody has been shown to bind to NB1-G cells by indirect immunofluorescence staining (Carachi et al., 1987 (Epenetos et al., 1982) , 100 ug antibody being incubated with 37 M Bq 1311. The iodination was allowed to proceed until optimal incorporation of the radiolabel had occurred. The efficiency of binding of 131I to antibody was determined by thin layer chromatography and binding efficiencies of 80-90% were routinely obtained.
NBI-G tumour spheroids
A human neuroblastoma cell line NB1-G was used for the study (Wheldon et al., 1985; Carachi et al., 1987 (Table IV) . Some preliminary work with larger spheroids was also undertaken.
Following the incubation period, the spheroids were washed by allowing them to sediment and draining off the incubation medium. This was replaced with 5ml of fresh medium containing 44 mM Nal. This procedure was repeated 6 times in total.
Spheroids were then transferred into individual agar coated wells of a 24 well test plate (Linbro) with one plate of cells being used for each universal container. The wells contained 0.5 ml medium having 15% FCS but no Nal added. Wells were replenished at weekly intervals with 0.5 ml fresh medium. The growth of spheroids was quantitated by measuring spheroid volume three times weekly using an image analysis system. Experiments were continued until 50% or more of the spheroids in each plate measured 1,000 im in diameter or for up to 30 days (as the wells would not accommodate further aliquots of fresh medium) whichever was the sooner. By 30 days there was a clear demarcation between regrowing and non-regrowing spheroids.
Results
The effect of radiolabelled UJ13A on NB1-G spheroid growth was determined by incubating spheroids with 2 activities of labelled monoclonal antibody and comparing this with the effect of Na[13 11]. The resulting growth curves are shown in Figure 1 . A lateral displacement of the growth curves is observed at the higher activity of 13 I-UJ13A. The indicated bars are -95% confidence limits on the median of log volume measured in pm3 (Colquohoun, 1971) . Table I shows the results of3 experiments where spheroids were exposed to a range of activities of 131I-UJ13A. Results are expressed as the median time taken for spheroids to reach 10 times the original volume, and the proportion of spheroids sterilised (i.e. failed to regrow by 30 days).
Both the proportion sterilised and the time taken for the spheroids to reach 10 times their original volume can be seen to increase with increasing activity of 13 I-UJ13A. At the highest activity of '3II-UJ13A used in experiments 1 and 2, more than half the spheroids were sterilised and therefore failed to reach x original volume so the median time to reach this endpoint cannot be defined, consequently only the proportion sterilised data are shown for this activity. These results should be compared with the effect of Na[131] on spheroid growth as summarized in Table II . This shows that spheroid growth is not visibly affected by Na ['3 II] at activity levels below 73 M Bq. This is 10 times the activity necessary to produce a comparable effect using 131I-UJ13A (see Table I ). 7.2 (6.8-7.8) 6.6 (6.3-6.9) 7.1 (6.8-7.5) 7.4 (7.2-7.9) 6.9 (5.9-8.0) 5.3 (4.7-6.1) 5.5 (4.9-6.3) 6.5 (6.0-6.9) 8.0 (7.4-8.2) 7.4 (6.9-7.9) 9.6 (8.3-11.2) 16.4 (13.2-21.8 Additional experiments have shown that UJ13A alone has no effect on spheroid growth, and that 1311 labelled human serum albumin, and 131I labelled monoclonal antibody T2.10, which does not bind to NB1-G cells, have only the same effect on spheroid growth as Na[131 I].
In order to determine if the spheroids are receiving a greater radiation dose from 1311-UJ13A during the 2h incubation period or during the month-long growth phase following the washing procedure, the activity of 1311-UJ13A associated with the spheroids was quantified immediately after the 6 washes in fresh medium and at time intervals during the period of spheroid growth. Results are shown in Table III . It can be seen that a much greater 1311 activity remains associated with spheroids exposed to 131I-UJ13A than with those exposed to Na [1311] .
An experiment was also conducted where the activity of 131I-UJ13A added to 3 aliquots of spheroids was approximately equal, but the length of the incubation time was varied. Table IV shows that the time for spheroids to reach 10 times the treatment volume increases with increasing length of incubation time. In the case of spheroids incubated for 2 h with '3II-UJl3A, the proportion sterilised was too great to allow evaluation of the spheroid growth endpoint.
The responses of two different sizes of spheroids, 200pm
and 450pm diameter, to incubation with varying levels of 131I-UJ13A are compared in Figure 2 . It can be seen that the effect of 13 I-UJl3A on the growth of both large and small spheroids is similar. It would appear from this result that both the large and the small spheroids are being irradiated to the same extent. 
Discussion
The results demonstrate a dose-response relationship between radiation damage, evaluated as a delay in spheroid growth or proportion spheroids sterilised, and the activity of 13'I associated with UJ13A at incubation. Similar activities of Na [1311] , however, were not found to affect growth of the spheroids, which would suggest that exposure to 13 1-UJI3A resulted in binding of the agent to the spheroids. This was supported also by the negative findings on incubation with similar activities of 131I-HSA and I311-T2 10. Studies with unlabelled UJ13A, which showed no effect on growth, would suggest that the effect on spheroid growth of 1311-UJl3A is radiation induced.
Significant effects were observed with Na[131 I] only at incubation activities of 180MBq where the estimated radiation dose during 2 h incubation (after allowing for rapid settling of the spheroids on the base of the incubation vessel) was in the region of 4 Gy, one half of the dose to a continuum of 131I at a concentration of 36 M Bq ml -1.
Some attempts were made to quantify the extent to which 131I-UJ13A was bound to the spheroids. In one study where spheroids were incubated with 38 M Bq for 2 h, it was found that at the end of the incubation period, and after repeated washing, -520 Bq of 1311 were associated with each spheroid. Using theoretical estimates (Humm, 1986) of the absorbed fraction of 131I #-particles for very small spheres (-200pm This result together with the observation that increasing time of exposure to 131I-UJ13A increases the effect on spheroid growth would suggest that the radiation dose is delivered partly by migration towards and binding of the radionuclide to the spheroids during the incubation period, and partly by a small amount of firmly bound residual activity being associated with each spheroid during the growth period.
It has been shown (Wheldon et al., 1985) that spheroids irradiated with 2.5Gy 4MeV X-rays as single acute exposures take 14 days to grow to 10 x original volume. NBI-G cells grown as spheroids have little capacity for repair of sub-lethal damage (Wheldon et al., 1986) therefore, the effect of protracted exposures should be similar to that of acute exposures of the same total dose. From Figure 1 it can be seen that 13.95 M Bq 1311 given as 131I-UJ13A also results in the spheroids requiring 14 days to grow to 10 x original volume. In addition the measured activities of 1311 associated with each spheroid would give a dose of the order of 2.5 Gy. This allows some comparison of the effect of antibodytargeted therapy and X-rays on spheroid growth in this system.
The A possible application of the spheroid model may be in evaluating antibody-targeted treatment using unfamiliar radionuclides. Short range a and 3 emitters, which will probably prove more useful than 1311 as therapeutic agents, present difficult dosimetric problems which are compounded by the increased importance of the distribution of the radionuclide conjugate within a tumour. Micrometastases though the most promising targets for antibody-guided therapy given systematically present the most difficult dosimetric problems (Humm, 1986 ). An in vitro model allowing operational evaluation of effective dose to micrometastases-like tumour cell populations delivered by antibody-conjugated radionuclides should be a useful experimental tool.
The NBl-G cell line has low capacity for repair of sublethal damage and therefore would not be expected to be significantly spared by low dose rate as activity falls. A tumour line with greater capacity for repair might be spared during the low dose rate phase of the growth period following the incubation. It is suggested that the experimental system described here provides a model for the quantitative evaluation of antibody-targeted therapy which could be applied to a number of different tumour types. Further study of the tumour spheroid model for radioimmuno-therapy of micrometastases therefore seems warranted.
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